J9020 HCPCS code: Injection, asparaginase, not otherwise specified, 10,000 units
J9020 is the HCPCS Level II code for injection, asparaginase, not otherwise specified, 10,000 units. CMS terminated J9020 on 2025-12-31; do not bill it for later dates of service. Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 1984-01-01 |
| Last action effective | 2026-01-01 |
| Terminated | 2025-12-31 |
What changed for J9020
- 1984-01-01: J9020 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9020?
J9020 is the HCPCS Level II code for injection, asparaginase, not otherwise specified, 10,000 units. Short descriptor: "Asparaginase, nos".
Does Medicare cover J9020?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
Related J90 codes
- J9000 — Injection, doxorubicin hydrochloride, 10 mg
- J9003 — Leuprolide injectable (camcevi etm), 1 mg
- J9010 — Injection, alemtuzumab, 10 mg
- J9011 — Injection, datopotamab deruxtecan-dlnk, 1 mg
- J9015 — Injection, aldesleukin, per single use vial
- J9017 — Injection, arsenic trioxide, 1 mg
- J9019 — Injection, asparaginase (erwinaze), 1,000 iu
- J9021 — Injection, asparaginase, recombinant, (rylaze), 0.1 mg
- J9022 — Injection, atezolizumab, 10 mg
- J9023 — Injection, avelumab, 10 mg
- J9024 — Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
- J9025 — Injection, azacitidine, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9020
- Watch J9020 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9020
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.